Abstract
Aim:Expression of PD-L1 in the tumor is associated with more favorable responses to anti-PD-1 therapy in multiple cancers. However, obtaining tumor biopsies for PD-L1 interrogation is an invasive procedure and challenging to assess repeatedly as the disease progresses.Materials & methods:Here we assess an alternative, minimally invasive approach to analyze blood samples for circulating tumor cells (CTCs) that have broken away from the tumor and entered the periphery. Our approach uses sized-based microfluidic CTC enrichment and subsequent characterization with microfluidic-based cytometry (chipcytometry).Conclusion:We demonstrate tumor-cell detection and characterization for PD-L1, and other markers, in both spiked and patient samples. This preliminary communication is the first report using chipcytometry for the characterization of CTCs.
Highlights
Establishment of PD-L1 & PD-L2 analysis by chipcytometry Flow cytometry was used to establish the specificity of the selected monoclonal antibodies for PD-L1 and PD-L2 on the non-small-cell lung cancer (NSCLC) cell lines A549 and H1975 (Figure 2A)
We demonstrate circulating tumor cells (CTCs) detection and PD-L1 and PD-L2 expression assessment on blood samples from patients with breast cancer
Future work will establish the utility of measuring the expression of PD-L1 on CTCs and whether this is reflective of expression in the tumor and predictive of response to treatment
Summary
Expression of PD-L1 in the tumor is associated with more favorable responses to anti-PD-1 therapy in multiple cancers
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
